The AstraZeneca share price has fallen almost 25% since late August. Is there value on offer for investors after this huge ...

Key Takeaways AstraZeneca shares declined Tuesday after reports that senior executives in China were potentially implicated ...

(Alliance News) - AstraZeneca PLC on Tuesday took the rare step of addressing a sharp fall in the company's share price. Shares in the Cambridge-based pharmaceuticals company slumped 8.2% to 10,138.10 ...

Analyst Etzer Darout of BMO Capital maintained a Buy rating on AstraZeneca (AZN – Research Report), retaining the price target of $89.00.

AstraZeneca's (NASDAQ:AZN) selloff on Tuesday in response to reports that the company is facing a fraud investigation in ...

AstraZeneca’s stock price dropped by 8.4% during Tuesday’s trading in London after a report fueled fears of a potentially ...

Upstream Bio garners analyst optimism for its lead drug verekitug, which could disrupt the $7.5 billion asthma biologics ...

AstraZeneca shares fell 8% in London Tuesday, the biggest drop in four years following a fresh report that a Chinese investigation of the company has widened. AstraZeneca said last week that its China ...

The FTSE 100 index fell slightly on Tuesday as a potential China probe negatively impacted AstraZeneca. Concurrently, U.S.

AstraZeneca shares recorded their biggest one-day drop since March 2020 on Tuesday following a report that dozens of senior ...

Chinese authorities detained AstraZeneca employees amid a probe into data privacy breaches and unlicensed drug sales, stock ...

AstraZeneca PLC shed £15 billion in market capitalization on Tuesday, after investors were underwhelmed by early data from a ...